SLP:NSC-Simulations Plus Inc. (USD)

EQUITY | Health Information Services | NASDAQ Capital Market

Last Closing

USD 44.69

Change

-0.96 (-2.10)%

Market Cap

USD 0.17B

Volume

0.08M

Analyst Target

USD 73.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Simulations Plus Inc designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
VEEV Veeva Systems Inc Class A

+2.17 (+1.07%)

USD 32.00B
SOLV Solventum Corp.

+0.87 (+1.34%)

USD 11.73B
DOCS Doximity Inc

-0.23 (-0.93%)

USD 4.83B
EVH Evolent Health Inc

+0.37 (+1.36%)

USD 3.36B
TDOC Teladoc Inc

+0.09 (+0.70%)

USD 2.20B
AGTI Agiliti Inc

N/A

USD 1.37B
PHR Phreesia Inc

-0.08 (-0.35%)

USD 1.16B
MPLN MultiPlan Corporation

-0.02 (-2.46%)

USD 0.43B
AMWL American Well Corp

-0.01 (-2.18%)

USD 0.17B
OWLT Owlet Inc

-0.35 (-7.87%)

USD 0.03B

ETFs Containing SLP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.13% 82% B 44% F
Dividend Return 0.27% 100% F 13% F
Total Return 0.13% 82% B 39% F
Trailing 12 Months  
Capital Gain 7.04% 91% A- 56% F
Dividend Return 0.57% 100% F 6% D-
Total Return 7.62% 91% A- 48% F
Trailing 5 Years  
Capital Gain 100.40% 75% C 87% B+
Dividend Return 5.38% 100% F 18% F
Total Return 105.78% 100% F 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 16.24% 91% A- 81% B-
Dividend Return 16.78% 91% A- 80% B-
Total Return 0.54% 100% F 13% F
Risk Return Profile  
Volatility (Standard Deviation) 50.89% 55% F 19% F
Risk Adjusted Return 32.98% 82% B 56% F
Market Capitalization 0.17B 42% F 54% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Health Information Services) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.30 38% 7%
Price/Book Ratio 5.19 33% 17%
Price / Cash Flow Ratio 40.38 8% 5%
Price/Free Cash Flow Ratio 49.52 17% 3%
Management Effectiveness  
Return on Equity 6.05% 75% 43%
Return on Invested Capital 4.01% 67% 39%
Return on Assets 4.32% 75% 67%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector